319 related articles for article (PubMed ID: 16834657)
1. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
Sato H; Minei S; Hachiya T; Yoshida T; Takimoto Y
Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
[TBL] [Abstract][Full Text] [Related]
2. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
Jenkins RB; Qian J; Lieber MM; Bostwick DG
Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
[TBL] [Abstract][Full Text] [Related]
3. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
[TBL] [Abstract][Full Text] [Related]
5. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization.
Qian J; Jenkins RB; Bostwick DG
Mod Pathol; 1997 Nov; 10(11):1113-9. PubMed ID: 9388062
[TBL] [Abstract][Full Text] [Related]
6. Genetic profile identification in clinically localized prostate carcinoma.
Gallucci M; Merola R; Leonardo C; De Carli P; Farsetti A; Sentinelli S; Sperduti I; Mottolese M; Carlini P; Vico E; Simone G; Cianciulli A
Urol Oncol; 2009; 27(5):502-8. PubMed ID: 18534873
[TBL] [Abstract][Full Text] [Related]
7. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage and grade.
Mahdy E; Pan Y; Wang N; Malmström PU; Ekman P; Bergerheim U
Anticancer Res; 2001; 21(5):3167-73. PubMed ID: 11848469
[TBL] [Abstract][Full Text] [Related]
9. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
10. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
[TBL] [Abstract][Full Text] [Related]
11. Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization.
Parrella P; Caballero OL; Sidransky D; Merbs SL
Invest Ophthalmol Vis Sci; 2001 Jul; 42(8):1679-84. PubMed ID: 11431428
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.
Sato K; Qian J; Slezak JM; Lieber MM; Bostwick DG; Bergstralh EJ; Jenkins RB
J Natl Cancer Inst; 1999 Sep; 91(18):1574-80. PubMed ID: 10491435
[TBL] [Abstract][Full Text] [Related]
13. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications.
Van Den Berg C; Guan XY; Von Hoff D; Jenkins R; Bittner ; Griffin C; Kallioniemi O; Visakorpi ; McGill ; Herath J
Clin Cancer Res; 1995 Jan; 1(1):11-8. PubMed ID: 9815882
[TBL] [Abstract][Full Text] [Related]
14. A molecularly genetic determination of prognostic factors of the prostate cancer and their relationships to expression of protein p27kip1.
Dvorácková J; Uvírová M
Neoplasma; 2007; 54(2):149-54. PubMed ID: 17319789
[TBL] [Abstract][Full Text] [Related]
15. Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer.
Mark HF; Samy M; Santoro K; Mark S; Feldman D
Exp Mol Pathol; 2000 Feb; 68(1):65-9. PubMed ID: 10640455
[TBL] [Abstract][Full Text] [Related]
16. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.
Rummukainen JK; Salminen T; Lundin J; Kytölä S; Joensuu H; Isola JJ
Mod Pathol; 2001 Oct; 14(10):1030-5. PubMed ID: 11598174
[TBL] [Abstract][Full Text] [Related]
17. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization.
Kubokura H; Tenjin T; Akiyama H; Koizumi K; Nishimura H; Yamamoto M; Tanaka S
Ann Thorac Cardiovasc Surg; 2001 Aug; 7(4):197-203. PubMed ID: 11578259
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma.
Gallucci M; Merola R; Farsetti A; Orlandi G; Sentinelli S; De Carli P; Leonardo C; Carlini P; Guadagni F; Sperduti I; Cianciulli AM
Cancer Lett; 2006 Jun; 237(1):76-82. PubMed ID: 16002207
[TBL] [Abstract][Full Text] [Related]
19. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
Alers JC; Krijtenburg PJ; Rosenberg C; Hop WC; Verkerk AM; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
Lab Invest; 1997 Nov; 77(5):437-48. PubMed ID: 9389787
[TBL] [Abstract][Full Text] [Related]
20. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma.
Takahashi S; Alcaraz A; Brown JA; Borell TJ; Herath JF; Bergstralh EJ; Lieber MM; Jenkins RB
Clin Cancer Res; 1996 Jan; 2(1):137-45. PubMed ID: 9816100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
